STOCK TITAN

Standard BioTools to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) announces participation in upcoming investor conferences to showcase breakthroughs in human health. President and CEO, Michael Egholm, PhD, to present at TD Cowen's 44th Annual Healthcare Conference and KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that management will participate in the following investor conferences:

  • TD Cowen’s 44th Annual Healthcare Conference on Wednesday, March 6, 2024. President and Chief Executive Officer, Michael Egholm, PhD, will present at 1:30 p.m. ET.
  • KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024. Egholm will participate in a fireside chat at 10:30 a.m. ET.

Presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Imaging Mass Cytometry, IMC, Hyperion, Hyperion XTi and XTi are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Available Information

Standard BioTools uses its website (standardbio.com), investor site (investors.standardbio.com), corporate X account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools website and its social media accounts in addition to following its press releases, SEC filings, public conference calls and webcasts.

Investor Contact: 

David Holmes
ir@standardbio.com  
  


FAQ

When will Standard BioTools Inc. participate in TD Cowen's 44th Annual Healthcare Conference?

Standard BioTools Inc. will participate in TD Cowen's 44th Annual Healthcare Conference on Wednesday, March 6, 2024.

Who will be presenting at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum?

President and CEO, Michael Egholm, PhD, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024.

Where can the live webcasts of the presentations be accessed?

The live webcasts of the presentations will be available on the Investor Relations page of the Company’s website at Events & Presentations.

Where can the archived recordings of the presentations be found?

The archived recordings of the presentations will be available on the Standard BioTools Investor Relations page at investors.standardbio.com.

Standard BioTools Inc.

NASDAQ:LAB

LAB Rankings

LAB Latest News

LAB Stock Data

939.60M
50.24M
0.69%
56.05%
2.67%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About LAB

fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.